ABBV or BMY or NVS

Key Takeaways

• AbbVie has successfully navigated the Humira patent cliff, with its next-generation immunology drugs Skyrizi and Rinvoq generating combined sales of approximately $24 billion in 2025 and positioning the company for high-single-digit revenue growth through 2029.
• Bristol-Myers Squibb is executing a major portfolio transition, with its Growth Portfolio expanding 17% to $26.4 billion in 2025 while Legacy Portfolio revenues face ongoing generic erosion, creating a complex risk-reward profile for investors.
• Novartis posted 8% net sales growth to $54.5 billion in 2025 with a core operating margin of 40.1%, though it faces what management describes as the largest patent expiry in its history in 2026.
• All three companies are actively pursuing acquisitions and pipeline investments, with AbbVie deploying over $30 billion in M&A (mergers and acquisitions) since early 2024, Bristol-Myers investing in strategic partnerships such as BioNTech, and Novartis committing $12 billion to acquire Avidity Biosciences.
• Dividend investors may find AbbVie's 5.5% increase in 2026 and Bristol-Myers' 17th consecutive annual increase attractive, while Novartis proposed a 5.7% dividend increase to CHF 3.70 per share.
• Market sentiment diverges significantly, with ABBV outperforming the S&P 500 by a wide margin over the past year, BMY trading at more modest valuations as it undergoes transformation, and NVS maintaining steady momentum despite looming patent headwinds.

Introduction

AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Novartis (NVS) represent three of the most closely watched names in the global pharmaceutical sector. Each company operates at the intersection of immunology, oncology, and neuroscience, yet they face distinctly different stages of portfolio evolution, patent cycles, and growth trajectories. This stock comparison is particularly timely as all three navigate the delicate balance between legacy drug erosion and new product launches. For investors seeking exposure to large-cap pharma with varying risk profiles — from the post-patent-cliff recovery story at AbbVie to the ongoing portfolio transformation at Bristol-Myers to the pre-patent-expiry positioning at Novartis — understanding the relative performance and market positioning of these three industry leaders is essential.

ABBV Overview and Recent Performance

ABBV (AbbVie Inc.), headquartered in North Chicago, Illinois, has emerged as one of the standout performers in the pharmaceutical sector over recent years. The company's defining narrative has been its successful navigation of the Humira loss of exclusivity — a patent cliff that once threatened more than 50% of its total revenue. In 2025, AbbVie delivered record net sales of approximately $61.2 billion, surpassing its initial expectations by more than $2 billion. This performance was powered by its immunology duo Skyrizi and Rinvoq, which together generated roughly $24 billion in annual sales. Skyrizi alone is now annualizing at nearly $18 billion, while Rinvoq exceeded $8 billion.

The company also demonstrated strength in neuroscience, with Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta all posting double-digit growth in recent quarters. However, challenges persist: the Aesthetics segment — including Botox Cosmetic and Juvederm — continues to face consumer spending headwinds, and Humira sales declined more than 50% through the first nine months of 2025. AbbVie has been highly active in business development, executing more than 30 M&A transactions since the start of 2024, including the $10.1 billion acquisition of Apogee Therapeutics. The company recently increased its quarterly dividend by 5.5% and settled Rinvoq patent litigation, extending exclusivity to 2037. With no significant loss of exclusivity events for the rest of the decade, AbbVie has guided for high-single-digit compound annual revenue growth through 2029.

BMY Overview and Recent Performance

BMY (Bristol-Myers Squibb Company), based in Princeton, New Jersey, is in the midst of a significant corporate transformation. The company reported full-year 2025 revenues of $48.2 billion, with its Growth Portfolio — which includes Opdivo, Opdualag, Breyanzi, Camzyos, Reblozyl, and Cobenfy — generating $26.4 billion, a 17% increase year over year. This growth has been crucial in offsetting the steady decline of the Legacy Portfolio, which includes products such as Revlimid, Pomalyst, and Sprycel facing generic competition. For 2026, management guided for revenue of approximately $46.0 billion to $47.5 billion and non-GAAP (non-Generally Accepted Accounting Principles) EPS (earnings per share) of $6.05 to $6.35.

Recent quarters have shown encouraging momentum in newer launches. The schizophrenia drug Cobenfy has demonstrated strong early uptake, surpassing adoption rates of other antipsychotic treatments in its first year. Breyanzi, a CAR-T cell therapy (a treatment that engineers a patient's own immune cells to attack cancer), has received expanded FDA (Food and Drug Administration) approval covering five cancer types. Camzyos for obstructive hypertrophic cardiomyopathy grew nearly 59% in Q4 2025. On the cost side, the company achieved $1 billion in savings during 2025 and remains on track toward a $2 billion productivity initiative. Bristol-Myers also increased its quarterly dividend to $0.63 per share, marking its 17th consecutive annual increase. The company's pipeline features multiple pivotal readouts expected in the back half of 2026, which management believes could better define the potential of its next wave of drug candidates.

NVS Overview and Recent Performance

NVS (Novartis AG), headquartered in Basel, Switzerland, has positioned itself as a pure-play innovative medicines company following the spin-off of its Sandoz generics business in 2023. For full-year 2025, Novartis posted net sales of $54.5 billion, an increase of 8% at constant currencies, with core operating income up 14%. The company achieved a core operating margin of 40.1%, driven by strong execution across its priority brands. Standout performers included Kisqali — the breast cancer drug that surged 68% in Q3 — Kesimpta for multiple sclerosis, Pluvicto for prostate cancer, and Scemblix for chronic myeloid leukemia, which nearly doubled sales year over year.

The company faces a critical juncture: its blockbuster heart failure drug Entresto began facing U.S. generic competition in mid-2025 after a federal judge denied Novartis' request to block a generic manufacturer. Entresto sales, which topped $8 billion annually, are projected to decline significantly in 2026. Tasigna and Promacta are also confronting generic erosion. To address these headwinds, Novartis has been aggressively reshaping its pipeline through acquisitions, most notably the $12 billion deal for Avidity Biosciences, which adds three late-stage neuroscience programs targeting neuromuscular diseases. Management extended its mid-term sales growth guidance to 5-6% annually through 2030 and raised peak sales estimates for Kisqali to over $10 billion and Scemblix to around $4 billion. Free cash flow reached $17.6 billion in 2025, supporting a proposed 5.7% dividend increase.

Trending AI Robots

In a market environment as dynamic as the current one, traders and investors are increasingly turning to AI-driven tools for timely, data-backed insights. Tickeron's Trending AI Robots page offers a curated selection of the platform's most effective AI trading bots — chosen from a database of hundreds of bots that trade thousands of different tickers. These bots are not randomly assembled; only those demonstrating strong alignment with prevailing market conditions earn a place in this featured section. Each bot operates with its own distinct trading style, strategy, timeframe, and performance metrics. Some bots focus on short-term swing trades while others pursue longer-duration trend-following approaches, and each is configured to trade a specific set of tickers. The result is a streamlined, real-time view of which algorithmic strategies are currently showing the strongest signals — offering a valuable complement to fundamental analysis for those monitoring stocks like ABBV, BMY, and NVS. Explore the Trending AI Robots to see which trading bots are capturing opportunities in the current market.

Head-to-Head Comparison

When comparing ABBV, BMY, and NVS, the most instructive lens is each company's position along the patent-cycle continuum. AbbVie sits in the most favorable spot: having already absorbed the Humira patent cliff, it now enjoys a decade-long runway with no significant additional loss of exclusivity events. Its Skyrizi-Rinvoq franchise provides visible, compounding growth that few large-cap peers can match. Bristol-Myers Squibb, by contrast, remains mid-transition — its Growth Portfolio is expanding rapidly at 17%, but the Legacy Portfolio still represents roughly 45% of revenue and faces relentless generic pressure, particularly from Revlimid and upcoming Eliquis patent expirations in certain markets. Novartis occupies an intermediate position: it has built impressive momentum with Kisqali, Kesimpta, Pluvicto, and Scemblix, yet 2026 marks what management calls the company's largest patent expiry year, centered on Entresto.

On valuation sensitivity, AbbVie trades at a forward price-to-earnings ratio of approximately 16-17x, reflecting market confidence in its post-Humira trajectory. Bristol-Myers trades at a lower multiple, consistent with its transitional status and near-term revenue headwinds, though its dividend yield and cost-cutting initiatives provide a floor for some investors. Novartis, with a market capitalization of roughly $288 billion, has seen its shares appreciate strongly — gaining over 27% year to date in recent periods — reflecting optimism about its pipeline and margin durability. In terms of geographic exposure, Novartis maintains the most internationally diversified revenue base, while AbbVie and Bristol-Myers are more heavily weighted toward the U.S. market. All three companies face regulatory and pricing uncertainty, including the potential impact of U.S. pharmaceutical tariff policies and drug pricing reforms, though AbbVie's voluntary agreement with the U.S. government has provided some insulation from these pressures.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability of growth drivers, and relative positioning against patent headwinds, Tickeron's AI analysis would likely favor ABBV among the three stocks in the current environment. The rationale is grounded in several measurable advantages: AbbVie has already cleared its most significant patent-cliff event, its two core growth assets — Skyrizi and Rinvoq — are demonstrating accelerating momentum with patent protection extended to 2037, and the company has no additional major loss of exclusivity risks for the remainder of the decade. This creates a comparatively clearer growth trajectory than Bristol-Myers, which must continue executing its portfolio transition while managing legacy erosion, or Novartis, which confronts its largest-ever patent expiry in 2026. That said, all three companies possess strong pipelines and proven commercial capabilities, and shifts in clinical data readouts, regulatory decisions, or macroeconomic conditions could alter relative positioning. The AI's probabilistic assessment leans toward AbbVie based on current trend data, but the analysis underscores that each stock presents a distinct risk-reward profile worthy of ongoing monitoring.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations